Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer (NCT03768570)

🧪 Interventions in This Study

• Durvalumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• Tom Baker Cancer Centre — Calgary, Alberta
• Cross Cancer Institute — Edmonton, Alberta
• BCCA - Vancouver Cancer Centre — Vancouver, British Columbia
• Health Sciences North — Greater Sudbury, Ontario
• Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
• Kingston Health Sciences Centre — Kingston, Ontario
• London Regional Cancer Program — London, Ontario
• Stronach Regional Health Centre at Southlake — Newmarket, Ontario
• Ottawa Hospital Research Institute — Ottawa, Ontario
• Thunder Bay Regional Health Sciences Centre/ — Thunder Bay, Ontario
• University Health Network — Toronto, Ontario
• The Jewish General Hospital — Montreal, Quebec
• The Research Institute of the McGill University — Montreal, Quebec
• Allan Blair Cancer Centre — Regina, Saskatchewan
• Saskatoon Cancer Centre — Saskatoon, Saskatchewan
• Hospital Clinic i Provincial — Barcelona,
• Hospital de la Santa Creu i Sant Pau — Barcelona,
• Hospital Clinico San Carlos — Madrid,
• Hospital 12 de Octubre — Madrid,
• Hospital Universitario La Paz — Madrid,
• Hospital Madrid Norte Sanchinarro — Madrid,
• Hospital Universitario Marques de Valdecilla — Santander,
• Instituto Valenciano de Oncologia — Valencia,
• Royal Devon and Exeter Hospital — Exeter, Devon
• Royal Cornwall Hospitals NHS Trust — Cornwall, England

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Bladder Cancer

• Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer — St Louis, Missouri
• Determinants of Bladder Cancer Recurrence Study (The DETER Study) — Basking Ridge, New Jersey
• Quality of Life in Patients With Bladder Cancer — New York, New York
• A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer — Hartford, Connecticut
• A Diagnostic for the Early Detection of Bladder Cancer — Long Beach, California

Explore by condition: All Bladder Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.